恒瑞医药(01276)截至1月27日累计回购股份907.37万股

智通财经01-27

智通财经APP讯，恒瑞医药(01276)发布公告，江苏恒瑞医药股份有限公司(以下简称“公司”)于2025年8月20日召开第九届董事会第十八次会议审议通过了《关于以集中竞价交易方式回购公司A股股份方案的议案》，同意公司使用自有资金，以集中竞价交易方式回购公司股份用于实施A股员工持股计划。回购价格不超过人民币90.85元/股(含)，回购资金总额不低于人民币10亿元且不超过20亿元。回购期限为自董事会...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2606207472?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-27 17:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606207472","market":"sh","top_or_hot":-1,"title":"恒瑞医药(01276)截至1月27日累计回购股份907.37万股","media":"智通财经","content":"<div>\n<p>智通财经APP讯，恒瑞医药(01276)发布公告，江苏恒瑞医药股份有限公司(以下简称“公司”)于2025年8月20日召开第九届董事会第十八次会议审议通过了《关于以集中竞价交易方式回购公司A股股份方案的议案》，同意公司使用自有资金，以集中竞价交易方式回购公司股份用于实施A股员工持股计划。回购价格不超过人民币90.85元/股(含)，回购资金总额不低于人民币10亿元且不超过20亿元。回购期限为自董事会...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1397998.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>恒瑞医药(01276)截至1月27日累计回购股份907.37万股</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n恒瑞医药(01276)截至1月27日累计回购股份907.37万股\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-27 17:46 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1397998.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，恒瑞医药(01276)发布公告，江苏恒瑞医药股份有限公司(以下简称“公司”)于2025年8月20日召开第九届董事会第十八次会议审议通过了《关于以集中竞价交易方式回购公司A股股份方案的议案》，同意公司使用自有资金，以集中竞价交易方式回购公司股份用于实施A股员工持股计划。回购价格不超过人民币90.85元/股(含)，回购资金总额不低于人民币10亿元且不超过20亿元。回购期限为自董事会...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1397998.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1655091616.SGD","symbol_name":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1397998.html","article_id":"2606207472","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606207472","pubTimestamp":1769507189,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"回购期限为自董事会审议通过回购股份方案之日起12个月以内。截至2026年1月27日，公司本次股份回购方案累计通过上海证券交易所交易系统以集中竞价交易方式回购股份907.37万股，已回购股份占公司总股本的比例为0.14%，购买的最高价为人民币70.00元/股，最低价为人民币57.20元/股，已支付的总金额为人民币6.05亿元。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600276":"恒瑞医药","LU1655091616.SGD":"JPMorgan Funds - China A-Share Opportunities A (acc) SGD","LU0359201612.USD":"贝莱德中国基金A2","LU2289578879.USD":"ALLIANZ CHINA A OPPORTUNITIES \"AT\" (USD) ACC","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H","LU1580142542.USD":"Blackrock Systematic China A-Share Opportunities A2 USD","LU1328615791.USD":"FULLERTON LUX FUNDS - ALL CHINA EQUITIES \"I\" (USD) ACC","LU1064130708.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"I\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1997245177.USD":"安联神洲A股基金","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","LU2580892789.USD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (USD) ACC","BK0196":"行业龙头","LU0405327148.USD":"ALLSPRING CHINA A FOCUS \"A\" (USD) ACC","LU1781817850.SGD":"Blackrock Systematic China A-Share Opportunities A2 SGD-H","LU1255011170.USD":"JPM CHINA A-SHARE OPPORTUNITIES \"A\" (USD) ACC","BK0239":"医药制造","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","LU1997245094.SGD":"安联神州A股基金AT Acc SGD","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU2580892862.HKD":"FRANKLIN SEALAND CHINA A-SHARES \"A\" (HKD) ACC","BK0183":"MSCI概念","LU1064131003.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"A\" (USD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU2495084118.USD":"ALLIANZ CHINA A-SHARES \"ATH\" (USDHDG) ACC","BK0188":"融资融券","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU1146622755.USD":"安本中国A股股票基金A Acc","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","BK0012":"证金概念","LU1997244956.HKD":"ALLIANZ CHINA A-SHARES \"AT\" (HKD) ACC A","LU0405327494.USD":"ALLSPRING CHINA A FOCUS \"I\" (USD) ACC","01276":"恒瑞医药","BK0028":"国家队","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK1191":"制药","LU2148510915.USD":"FULLERTON LUX FUNDS - CHINA A EQUITIES \"R\" (USD) ACC","BK0060":"抗癌"},"translate_title":"Hengrui Medicine (01276) has repurchased a total of 9.0737 million shares as of January 27","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600276":1.5,"01276":1.5},"content_text":"智通财经APP讯，恒瑞医药(01276)发布公告，江苏恒瑞医药股份有限公司(以下简称“公司”)于2025年8月20日召开第九届董事会第十八次会议审议通过了《关于以集中竞价交易方式回购公司A股股份方案的议案》，同意公司使用自有资金，以集中竞价交易方式回购公司股份用于实施A股员工持股计划。回购价格不超过人民币90.85元/股(含)，回购资金总额不低于人民币10亿元且不超过20亿元。回购期限为自董事会审议通过回购股份方案之日起12个月以内。2026年1月，公司通过上海证券交易所交易系统以集中竞价交易方式回购股份17.5万股，已回购股份占公司总股本的比例为0.003%，购买的最高价为人民币57.48元/股，最低价为人民币57.20元/股，已支付的总金额为人民币1003.86万元(不含交易费用)。截至2026年1月27日，公司本次股份回购方案累计通过上海证券交易所交易系统以集中竞价交易方式回购股份907.37万股，已回购股份占公司总股本的比例为0.14%，购买的最高价为人民币70.00元/股，最低价为人民币57.20元/股，已支付的总金额为人民币6.05亿元(不含交易费用)。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,buyback","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606207472","isCrawlerRequest":true}